RecruitingNot ApplicableNCT07306741

Cognitive and Fusion Prostatic Biopsy

Cognitive Versus Image Guided Fusion Transrectal Prostatic Biopsy for the Detection of Prostate Cancer

Sponsor

Menoufia University

Enrollment

80 participants

Start Date

Dec 28, 2025

Study Type

INTERVENTIONAL

Conditions

Prostate Cancer

Summary

The goal of this study is to compare two different prostate biopsy techniques used to detect prostate cancer. These techniques are cognitive-targeted biopsy (CTB) and magnetic resonance imaging-ultrasound fusion-targeted transrectal biopsy (FTB). Both methods aim to improve the accuracy of prostate cancer detection by targeting suspicious areas identified on prostate imaging. This study will compare how accurately each technique detects prostate cancer, the pathological findings obtained from each biopsy method, and how operator performance may influence the procedure. The information gained from this study may help improve prostate cancer diagnosis and guide future biopsy practices.

Eligibility

Sex: MALE

Plain Language Summary

Simplified for easier understanding

This study compares two biopsy techniques — cognitive fusion and MRI/ultrasound fusion-guided biopsy — for detecting prostate cancer in men who have never had a prostate biopsy before and whose MRI showed suspicious lesions. **You may be eligible if...** - You have never had a prostate biopsy before - Your PSA (prostate-specific antigen) level is between 4 and 20 ng/mL - Your prostate MRI showed a suspicious score of 4 or 5 out of 5 (PI-RADS 4 or 5) **You may NOT be eligible if...** - You have had a previous prostate biopsy - Your PSA level is outside the 4–20 ng/mL range - You have a contraindication to MRI (such as certain implants or severe claustrophobia) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.